The Invesco NASDAQ 100 ETF (QQQM) has outperformed its peers with a 40% return in 12 months, driven by AI spending. The fund, a lower-cost alternative to QQQ, will undergo its first quarterly rebalance under new Nasdaq-100 rules on June 22, 2026, which will affect constituent eligibility and weighting. Investors are weighing the benefits of its concentrated tech portfolio against potential risks like sector rotation or valuation corrections.

Lam Research Senior Vice President, Neil J. Fernandes, sold 7,659 shares of common stock at $309.60 per share under a pre-arranged Rule 10b5-1 trading plan. This transaction, valued at approximately $2.37 million, is considered a routine liquidity event given that Fernandes still retains a substantial holding of 58,470 direct shares and 1,015.395 indirect shares. The sale, adopted on November 17, 2025, reflects a planned rather than opportunistic disposition of stock.

Boeing (BA) shares have outperformed the aerospace-defense industry over the past six months, rising 9.1% while the industry declined 1%. This outperformance is driven by strong commercial and defense order activity, substantial backlogs, and a promising outlook for the aviation services market. Despite these positives, Boeing faces challenges including high debt levels and poor return on invested capital, suggesting that new investors might consider waiting for a better entry point, while existing investors may want to retain their holdings.

Rocket Lab (NASDAQ:RKLB) is highlighted as the only publicly tradable pure-play space company that even SpaceX acknowledges as a competitor. The article discusses Rocket Lab's strong backlog, the upcoming Neutron rocket launch for medium-lift payloads, and significant defense contracts, positioning it as a potential "second SpaceX-shaped business." Despite its potential, the company faces risks including a net loss, high valuation (122 times sales), and a slipping Neutron launch schedule.

Stardust Power Inc. (SDST) held its AGM 2026, where all but one of the five key proposals were approved by stockholders. The meeting included board introductions, a Q&A session, and the final voting outcomes are pending disclosure in a Form 8-K.

Scienture Holdings Inc. (SCNX) has been awarded U.S. Patent No. 12,622,903 B2 for its Rezenopy Nasal Spray, effective until 2041, which solidifies its position in the healthcare market for CNS treatments. Although this patent enhances commercial viability, the company faces financial challenges, as indicated by declining revenue and a low profitability score, suggesting a mixed outlook for investors. The patented product will be manufactured by Summit Biosciences, allowing Scienture to focus on sales and marketing.

Ademi LLP is investigating Rallybio (Nasdaq: RLY) regarding its recently announced transaction with Avenzo Therapeutics, citing potential breaches of fiduciary duty and other legal violations. Rallybio equityholders are expected to own only 2.8% of the combined company, while Avenzo equityholders will own 97.2%. The firm is examining whether Rallybio's board of directors is fulfilling its fiduciary duties to all shareholders, especially given that Rallybio insiders are set to receive substantial benefits and the transaction agreement imposes a significant penalty on competing bids.

Jack Henry (JKHY) has integrated its Payments Orchestrator into Aeropay's platform, enhancing Aeropay's instant payment and pay-by-bank features. This collaboration aims to improve efficiency and resilience in payment processing, benefiting both companies in the digital economy. Jack Henry's strong GF Score™ of 86/100 and robust financial metrics suggest solid growth potential, despite its current P/E ratio of 19.1 being near its 10-year low.

Valero Energy Corp (NYSE: VLO) has scheduled its Q2 2026 earnings release for July 30, 2026, with a conference call following at 10:00 a.m. Eastern Time. The stock is currently trading near its 52-week high, with recent fund flows indicating strong institutional interest. The upcoming earnings report is expected to be a significant focal point for investors, especially given the company's previous quarter's strong performance, exceeding analyst expectations in EPS and revenue.

Charles River Laboratories International, Inc. (CRL) outlined a strategy at the 46th Annual William Blair Growth Stock Conference emphasizing operational efficiency, portfolio refinement, and technology-driven growth, including AI and NAMs. The company reaffirmed its financial guidance, expecting margin expansion and renewed organic growth, while strengthening its global position, particularly in China, and maintaining its leadership in drug development innovation.